Antineoplastic Agents, Immunological

"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000074322
MeSH Number(s)	D27.505.954.248.384
Concept/Terms	Antineoplastic Agents, Immunological Antineoplastic Agents, Immunological Immunological Antineoplastic Agents Antineoplastics, Monoclonal Antibodies Antineoplastics, Monoclonal Antibodies Antibodies Antineoplastics, Monoclonal Monoclonal Antibodies Antineoplastics Monoclonal Antibodies, Antineoplastic Antineoplastic Monoclonal Antibodies Antineoplastic MAbs Antineoplastics, Monoclonal Antibody Monoclonal Antibody Antineoplastics MAbs, Antineoplastic

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Immunological [D27.505.954.248.384]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Immunological".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.

Bar chart showing 12 publications over 4 distinct years, with a maximum of 4 publications in 2017 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2016	1	1	2
2017	4	0	4
2018	3	1	4
2019	1	1	2

Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.

Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019 10; 7(10):1570-1573.

View in: PubMed
Lennon S, Oweida A, Milner D, Phan AV, Bhatia S, Van Court B, Darragh L, Mueller AC, Raben D, Martínez-Torrecuadrada JL, Pitts TM, Somerset H, Jordan KR, Hansen KC, Williams J, Messersmith WA, Schulick RD, Owens P, Goodman KA, Karam SD. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clin Cancer Res. 2019 06 01; 25(11):3352-3365.

View in: PubMed
Ahmed M. Checkpoint inhibitors: What gastroenterologists need to know. World J Gastroenterol. 2018 Dec 28; 24(48):5433-5438.

View in: PubMed
Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018 10; 6(10):1129-1135.

View in: PubMed
Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244.

View in: PubMed
Minion LE, Tewari KS. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018 03; 148(3):609-621.

View in: PubMed
Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 Dec; 18(12):1610-1623.

View in: PubMed
Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, Cristofanilli M, Rosellini P, Generali D. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. Eur J Cancer. 2017 11; 86:257-265.

View in: PubMed
Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24; 10(1):97.

View in: PubMed
Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement